SJOGREN’S SYNDROME MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Sjogren’s syndrome is systematic autoimmune disorder which effect the entire body, along with complication such as, chronic pain, major organ involvement, profound fatigue, neuropathies and Sjogren’s syndrome zmphomas.

For the treatment of Sjogren’s syndrome different medication such as methotrexate available to manage the syndrome. Currently no single medication has been conclusively proven to treat the progression of Sjogren’s.

Antimalarial Quinolines, Cholinergic Agonists and Corticosteroids are the prescription drug used for the treatment of Sjogren’s.

Market Dynamics

Increasing prevalence of Sjogren’s syndrome is expected to drive the market growth during the forecast period.

For instance, according to the Sjogren’s Foundation 2021, around 3 to 4 million people in the U.S. suffer from Sjogren’s syndrome which is as common as rheumatoid arthritis (RA), and three times as common as systemic lupus erythematosus (SLE).

Key features of the study:

• This report provides an in-depth analysis of the global sjogren’s syndrome market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global sjogren’s syndrome Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global sjogren’s syndrome Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sjogren’s syndrome Market

Detailed Segmentation:

• Global Sjogren’s Syndrome Market, By Drug:
  • Antimalarial Quinolines
  • Cholinergic Agonists
  • Corticosteroids
  • Others (Pain Relief Medication and late phase drug)
• Global Sjogren’s Syndrome Market, By Type:
  • Primary
  • Secondary
• Global Sjogren’s Syndrome Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Sjogren’s Syndrome Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
      • Russia
      • Rest Of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • ADVANZ Pharma *
    • Company Overview
    • Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Novartis/MorphoSys
  • RemeGen
  • Resolve Therapeutics
  • TearSolutions
  • VIELABIO
  • Otsuka Pharmaceutical Co., Ltd.
  • Bridge Pharma Inc.

“*” marked represents similar segmentation in other categories in the respective section.